Capsid inhibitors: Scientists find novel, potent HIV agents with long-acting potential | CROI

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Researchersidentified novel HIV-1 capsid inhibitors (CAIs) with uniquely potent antiviral activity and a favorable resistance profile orthogonal to existing antiretrovirals (ARVs). 

Why this matters

  • While HIV capsid (CA) plays an essential role in multiple stages of the viral life cycle, it remained an unexplored target for ARV therapy. 

Key results

  • They identified GS-CA1, an exemplified member of a novel class of CAIs, as a highly potent inhibitor of HIV-1 replication in T cell lines (EC50 = 0.24 nM) that displays similar potency against multiple HIV-1 clinical isolates from all major clades in huma...